Bayer To Retain Kogenate Line Following Plasma Unit Spin-Off
This article was originally published in The Pink Sheet Daily
Executive Summary
Company divests plasma products business to NPS BioTherapeutics under a $590 mil. agreement. Bayer will receive 10% equity in NPS, a new corporation formed by Cerebus Capital Management and Ampersand Ventures.
You may also be interested in...
Talecris Immunoglobulin Therapy Gains Priority Review For CIDP
Supplemental BLA for chronic inflammatory demyelinating polyneuropathy has Sept. 13 user fee date.
Talecris Immunoglobulin Therapy Gains Priority Review For CIDP
Supplemental BLA for chronic inflammatory demyelinating polyneuropathy has Sept. 13 user fee date.
Crucell Inks European Distribution Deal With Sanquin For Cofact
Pact compliments April agreement with U.S. Bayer spin-off Talecris Biotherapeutics to distribute Prolastin.